

RESEARCH ARTICLE OPEN ACCESS

New Anti-Angiogenic Therapy for Glioblastoma With the Anti-Depressant Sertraline

Nobushige Tsuboi^{1,2} | Yoshihiro Otani¹ | Atsuhito Uneda¹ | Joji Ishida¹ | Yasuki Suruga¹ | Yuji Matsumoto¹ | Atsushi Fujimura^{2,3} | Kentaro Fujii¹ | Hideki Matsui^{2,3} | Kazuhiko Kurozumi⁴ | Isao Date¹ | Hiroyuki Michiue²

¹Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan | ²Neutron Therapy Research Center, Okayama University, Okayama, Japan | ³Department of Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan | ⁴Department of Neurosurgery, Hamamatsu University School of Medicine, Shizuoka, Japan

Correspondence: Hiroyuki Michiue (hmichiue@md.okayama-u.ac.jp)

Received: 26 March 2024 | Revised: 18 July 2024 | Accepted: 20 September 2024

Funding: This study was supported by a Grant-in-aid for Takeda Science Foundation (2016049889 to H. M.), Scientific Research JSPS KAKENHI (Grant Number JP18K08944, JP21K09176, and JP24K12263).

Keywords: anti-angiogenic therapy | antidepressant sertraline | drug repositioning | glioblastoma | tumor derived endothelial cells

ABSTRACT

Background and Aims: Anti-angiogenic therapies prolong patient survival in some malignancies but not glioblastoma. We focused on the relationship between the differentiation of glioma stem like cells (GSCs) into tumor derived endothelial cells (TDECs) and, anti-angiogenic therapy resistance. Especially we aimed to elucidate the mechanisms of drug resistance of TDECs to anti-angiogenic inhibitors and identify novel anti-angiogenic drugs with clinical applications.

Results: The mouse GSCs, 005, were differentiated into TDECs under hypoxic conditions, and TDECs had endothelial cell characteristics independent of the vascular endothelial growth factor (VEGF) pathway. In vivo, inhibition of the VEGF pathway had no anti-tumor effect and increased the percentage of TDECs in the 005 mouse model. Novel anti-angiogenic drugs for glioblastoma were evaluated using a tube formation assay and a drug repositioning strategy with existing blood-brain barrier permeable drugs. Drug screening revealed that the antidepressant sertraline inhibited tube formation of TDECs. Sertraline was administered to differentiated TDECs in vitro and 005 mouse models in vivo to evaluate genetic changes by RNA-Seq and tumor regression effects by immunohistochemistry and MRI. Sertraline reduced Lama4 and Ang2 expressions of TDEC, which play an important role in non-VEGF-mediated angiogenesis in tumors. The combination of a VEGF receptor inhibitor axitinib, and sertraline improved survival and reduced tumor growth in the 005 mouse model.

Conclusion: Collectively, our findings showed the diversity of tumor vascular endothelial cells across VEGF and non-VEGF pathways led to anti-angiogenic resistance. The combination of axitinib and sertraline can represent an effective anti-angiogenic therapy for glioblastoma with safe, low cost, and fast availability.

1 | Introduction

Glioblastoma is a lethal malignant brain tumor that is characterized by a high degree of angiogenesis and tumor invasion [1]. Even with new advances in multidisciplinary treatments for glioblastoma, the median survival is still <2 years [2–4]. Most anti-cancer drugs, including molecularly targeted drugs, are ineffective for glioblastoma owing to the presence of the blood-brain barrier (BBB) and various other brain-specific obstacles [5, 6].

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd

20457634, 2024, 20, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/cam4.70288 by Okayama University, Wiley Online Library on [25/05/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms -and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

Anti-angiogenic therapy for malignant tumors aims to suppress tumor growth by inhibiting tumor vascular growth, thus cutting off nutrients and oxygen to the tumor [7, 8]. Bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor A (VEGFA) and an anti-angiogenic treatment, is an effective treatment for several malignant tumors including colorectal, ovarian, and non-small cell lung cancer [9-11]. Recent phase III clinical studies of three VEGF inhibitors (VEGF antibody, VEGFR-2 antibody, and VEGFR-TK inhibitor) for colorectal cancer have reported efficacy [12-14]. Bevacizumab has been approved by the FDA for recurrent glioblastoma since it prolongs progression free survival and reduces steroid requirement [15]. However, bevacizumab did not demonstrate therapeutic effects in glioblastoma in randomized phase III trials (AVAglio, RTOG-0825, EORTC-26101) [16, 17]. Furthermore, there are various reports on the formation of tumor blood vessels, including angiogenesis, and vascular mimicry, with different constitutive vascular endothelial cells and expressed genes [18].

Tumor derived endothelial cells (TDECs) are derived from glioma stem like cells (GSCs) [19]. GSCs differentiate into ectodermal cells and vascular endothelial cells, which are mesodermal [20, 21]. However, there are few reports on the resistance to treatment with TDECs in glioblastoma, and there are no reports of TDECs as therapeutic targets.

In this paper, we examined the mechanism of resistance by TDECs to anti-angiogenic therapy targeting the VEGF pathway and developed a novel anti-angiogenic drug for clinical application. Our results identify sertraline as a potential new anti-angiogenic therapy targeting TDECs.

2 | Materials and Methods

2.1 | Cell Culture

The mouse GSC, 005, was provided by Dr. Tomotoshi Marumoto and Dr. Inder Verma and cultured as previously described [22]. To differentiate into TDECs, 005 cells were cultured in the EGM-2 BulletKit medium (Lonza, Basel, Switzerland) under hypoxic conditions (1% O₂). U87 Δ EGFR was provided from Dr. Balveen Kaur (University of Texas Health Science Center, Houston, TX, USA) and cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal bovine serum (37°C, 5% CO₂). We cultured human umbilical vein endothelial cells (HUVECs) (Takara Bio Inc., Shiga, Japan) in EGM-2 BulletKit medium, mouse brain microvascular endothelial cells (MBMECs) (Cell Biologics, Chicago, USA) in a Complete Medium Kit With Serum and culture boost-R (4Z0-500-R, Cell Systems, Kirkland, USA).

2.2 | Animals and Animal Model

All animal studies were performed following Okayama University ethical guidelines for experimental animal care (OKU-2018838, OKU-2019568, OKU-2020793, OKU-2021590). 6-week-old female BALB/c-nu/nu mice were purchased from SHIMIZU Laboratory Supplies Co, Ltd. (Kyoto, Japan). 005 (5×10^4 cells) or U87 Δ EGFR

 $(3 \times 10^5$ cells) were transplanted into the right frontal lobe of generally anesthetized mice. We administered LEAF (Ultra-LEAF Purified anti-mouse VEGF-A Antibody, BioLegend, San Diego, USA: 2.5 mg/kg, twice a week) or Axitinib (S1005, Selleck, Houston, USA: 25 mg/kg, dissolved in Polysorbate 80 and acidified water, every other day) or vehicle solution intraperitoneally, starting on Day 14 (005) or Day 5 (U87 Δ EGFR) after tumor cell transplantation. Sertraline hydrochloride (S0507, Selleck: 25 mg/kg) or diluted water was injected subcutaneously daily starting on Day 14 for the 005 mouse model.

2.3 | Gene Analysis

Total RNA was isolated from 005, TDECs differentiated by the method described above, TDECs treated with sertraline (5μ M) and MBMECs using RNeasy kit (Qiagen, Santa Clarita, CA, USA), and samples were analyzed using Poly(A) mRNA Magnetic Isolation Module (New England Biolabs, MA, USA) for Poly(A) RNA preparation, NEBNext UltraII Directional RNA Library Prep Kit for Illumina (New England Biolabs, MA, USA) for library preparation and NovaSeq 6000 (Illumina Inc., SanDiego, CA) for sequencing. The RNA sequence analyses were performed by Rhelixa (Tokyo, Japan).

A significant change in gene expression was defined as an absolute fold change in expression of 2.0 with a p < 0.05 or a q < 0.05 compared with appropriate controls. The RNA sequence data were deposited in the Gene Expression Omnibus (GEO) under accession number GSE199495 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE199495). The data were analyzed with GraphPad Prism9 (GraphPad, San Diego, CA, USA) and RIAs provided by Rhelixa. Enrichment analysis was performed through Metascape (https://metascape.org/gp/index.html#/main/step1).

2.4 | Tube Formation Assay

TDECs $(3 \times 10^4 \text{ cells/well})$ and MBMECs $(3 \times 10^4 \text{ cells/well})$ were seeded on Matrigel Growth Factor Reduced Basement Membrane (354230, Corning). Cells were treated with anti-VEGF antibodies and various drugs. After 12 or 24 h, images were obtained, and the total tube length was measured with fluorescence microscope (BZ-X800; Keyence).

2.5 | Cell Proliferation Assay

TDECs (2×10⁴ cells/well), U87 Δ EGFR (1×10⁴ cells/well), and MBMECs (1×10⁴ cells/well) were seeded in 96-well plates. After 24 h, cells were treated with drugs. Cells were then incubated with WST-1 and absorbance at 438 nm was measured at 30 min, 1 h, 2 h, and 4 h.

2.6 | Drug Screening

Nineteen drugs were adjusted to final concentrations of 0, 1, 5, and $10 \mu M$, and tube formation assay and cell proliferation assay were performed. The IC50 was calculated using Excel software.




FIGURE 1 | Legend on next page.

FIGURE 1 | Tumor-derived endothelial cells (TDECs) differentiated from pluripotent glioma stem like cells (GSCs, 005). (A) Schema of differentiation of 005, a mouse GSC line, to TDECs, neural, and glial cells. (B–D) Immunocytochemistry of 005 cells (B) and TDECs (C), neural cells, and glial cells (D) differentiated from 005 cells. (E, F) Heatmap and principal component analysis (PCA) of genes of 005 cells, TDECs on Day 2, and TDECs on Day 5 detected by RNA-Seq (n=3). (G) Enrichment analysis of GO terms associated with up-regulated genes in TDECs compared with genes in 005 cells. (q<0.05, log_2 fold change (gene expression of TDECs/005s)>1). (H) Western blot analysis of VEGFR-2 in 005 cells, TDECs, and mouse brain microvascular endothelial cells (MBMECs).

2.7 | Magnetic Resonance Imaging (MRI)

MRI was taken with the approval of the animal study protocol (OKU-2021590). Glioma model mice were generally anesthetized with isoflurane and given a gadolinium contrast medium (Gadovist, Bayer, Japan). The mice were screened with highresolution axial T2-weighted images using a Rapid Acquisition with Relaxation Enhancement (RARE) sequence to evaluate brain tumor size and to monitor its evolution stage, using repetition time (TR)/effective echo time (TE) = 1200/8 ms. MRI data of the mice were acquired and processed by using ParaVision 5.1 software (Bruker BioSpec 4.7 T, Ettlingen, Germany).

2.8 | Immunohistochemistry (IHC)

Samples were treated with primary antibody (CD31: DIA-310, Dianova, LAMA4: PAB26919, Abnova) and secondary antibody (anti-Rat antibody: A11007, Invitrogen, anti-Rabbit antibody: ab150072, Abnova). The samples were observed by confocal laser microscope ZEN (ZEISS, Germany). To avoid differences due to the choice of field of view, all tumors were observed at weak magnification so that all blood vessels within the tumor in one slide could be counted. To avoid subjective judgments, observations, measurements, and evaluations were performed by two or more skilled experimenters; luminal structures that expressed CD31 and had no tumor cells or other cells inside were counted as vessels.

2.9 | Western Blotting

Proteins from 005 cells cultured in various conditions were separated by SDS-PAGE and transferred to a PVDF membrane. The membrane was probed with rabbit anti-VEGF Receptor 2 antibody (Cell Signaling Technology) and mouse anti- β -actin antibody (A5441, Sigma-Aldrich), followed by probing with HRP-labeled anti-rabbit IgG (#7074S, Cell Signaling Technology) and HRPlabeled anti-mouse IgG (#7074S, Cell Signaling Technology). Bands were detected using an ECL Prime kit (GE Healthcare).

2.10 | Statistical Analysis

All data are represented as the mean standard error of the mean (SEM). Kaplan–Meier survival curves were generated by using GraphPad Prism9 software and the log-rank (Mantel-Cox) test was performed to assess statistical significance between groups. The Unpaired Student's t-test was used to compare two groups.

Comparisons between multiple groups were performed with one-way ANOVA with Tukey's multiple comparisons tests. *p*-values were designated as *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.001, and ns non-significant ($p \ge 0.05$).

3 | Results

3.1 | Differentiation of TDECs From Pluripotent 005 GSCs

We differentiated 005 cells with GFP into TDECs or neural/ glial cells (Figure 1A) or checked stem cell markers such as Oct3/4 and CD133 [22] (Figure 1B). After 5 days of culture in specific conditions, the differentiated cells were confirmed as TDECs or neural and glial cells, as shown by endothelial cell markers CD31 and CD34 or Neu-N and GFAP, respectively (Figure 1C,D, and Figure S1A). Nevertheless, U87∆EGFR did not differentiate into endothelial cell in same way (Figure S1B). The RNA-seq in 005 and TDECs on Days 2 and 5 of differentiation was performed to evaluate the process of differentiation GSCs to TDECs. Hierarchical clustering heatmap and principal component analysis (PCA) showed that each group differentiated over time (Figure 1E,F). Enrichment analysis was then performed between 005 and TDECs on Day 5, and the top gene signature was blood vessel morphogenesis (112 genes) (q < 0.05, fold change (gene expression of TDEC/005) > 2, -LogP = 21.15205) (Figure 1G and Figure S2). Western blot analysis showed that VEGFR-2 was not expressed in TDECs (Figure 1H).

3.2 | Effect of VEGF Pathway Inhibitors (Anti-VEGF Antibody or VEGFR Inhibitor) on Brain Tumor Model Using Two Types of Cell Lines

Next, U87 Δ EGFR brain tumor model mice were treated with axitinib, VEGFR and multi-kinase inhibitor (Figure 2A). Median survival time was 15 days in the control group and 20 days in the axitinib group (log-rank test, p = 0.0002, Figure 2B). Average survival time was 14.9 ± 0.32 days in the control group and 19.6 ± 1.03 days in the axitinib group (unpaired *t*-test, p = 0.0016, Figure 2C). CD31 immunohistochemical staining revealed the number of tumor blood vessels (HPF, 10×) in the axitinib group (4.27 ± 0.78/1HPF) and in the control group (9.75 ± 1.65/1HPF) (Unpaired *t*-test, p = 0.0128, Figure 2D). Furthermore, HE staining and MRI results of tumors 9 days after drug administration demonstrated a remarkable tumor suppressive effect and necrotic lesion in the axitinib group (Figure 2E,F).




FIGURE 2 | Legend on next page.

FIGURE 2 | Inhibition of the VEGF pathway is ineffective in the GSC-transplanted mouse tumor model and results in tumor vascular growth composed of TDECs. (A) Administration protocol for axitinib (VEGFR inhibitor) to mice transplanted with U87 Δ EGFR cells. (B) Kaplan–Meier survival curve of control and axitinib-treated U87 Δ EGFR brain tumor model mice (log-rank test, *p* = 0.0002). (C) Box plot for survival (days) of the control and the axitinib groups (unpaired *t*-test, *p* = 0.0016). (D) Graph of the average number of blood vessels per field of view in tissue immunostaining in the control and the axitinib groups. (E) HE staining and gadolinium contrast-enhanced MRI of two groups on Day 9 after the start of treatment (bar: 1 mm). (F) Intra-tumor necrosis image (HE staining) in the axitinib group (below the dotted line: Necrotic area; arrowhead: Necrotic cells). (G) Administration protocol for axitinib and LEAF (anti-mouse VEGF antibody) to brain tumor mouse model derived from 005 cells. (H) Kaplan–Meier survival curve of control and axitinib-treated 005 mouse model (log-rank test, *p* = 0.224). (I) Comparison of tumor volume on MRI (control vs. LEAF: *p* = 0.7266; control vs. Axitinib: *p* = 0.7606). (J) Comparison of the average number of blood vessels per field of view in tissue immunostaining (control vs. axitinib: *p* > 0.05). (K, L) Nuclear staining of tissue and gadolinium contrast-enhanced MRI 2 weeks after initiation of treatment (bar: 1 mm). (M) Comparison of TDECs and non-TDECs of intra-tumor vascular endothelial cells by immunohistochemistry of CD31 (CD31: Red, 005: Green by GFP, nuclear staining: Blue). (N) Number of tumor blood vessels in the tumor after anti-angiogenic therapy (LEAF, axitinib) and the ratio of TDEC/non-TDEC in immunohistochemistry. * indicates significant differnce.

The 005 model with axitinib showed 37 days (control) and 38.5 days (axitinib) in median survival time, respectively (log-rank test, p=0.224, Figure 2G,H). The tumor volume (mean ± SEM) on MRI at 2 weeks after drug administration was $18.85\pm6.82\,\text{mm}^3$ (control) and $22.25\pm5.90\,\text{mm}^3$ (LEAF) (unpaired *t*-test, p=0.727); the tumor volumes were $18.35\pm2.85\,\text{mm}^3$ (control) and $16.34\pm5.59\,\text{mm}^3$ (axitinib), respectively (Unpaired *t*-test, p=0.761) (Figure 2I–L). Furthermore, the number of tumor blood vessels was $30.7\pm10.4/1\text{HPF}$ (control) and $23.6\pm7.2/1\text{HPF}$ (axitinib) (Unpaired *t*-test, p=0.3920, Figure 2J). Together these results indicate that LEAF and axitinib treatment had no tumor reduction effect on tumors derived from 005.

TDECs or non-TDECs, which were endothelial cells derived from normal brain tissue, bone marrow, or mesenchymal stem cells, but not differentiated from GSCs, were evaluated by the CD31immunostaining and 005-derived GFP (Figure 2M). In LEAF group and axitinib group, both the proportion and number of non-TDECs decreased compared with those in the control group (75% and 47%, control group vs. LEAF group; 79% and 62%, control group vs. axitinib group) and the proportion and number of TDECs increased (25% and 53%, control group vs. LEAF group; 21% and 38%, control group vs. axitinib group) (Figure 2N).

The administration of axitinib to the 005 mouse model had no prognostic survival effect, but on the contrary induced tumor vascular growth.

3.3 | Differences in Ex Vivo Angiogenesis and Genetic Characteristics Between TDECs and Normal Vascular Endothelial Cells

The tube formation assays were performed to evaluate the antiangiogenic effects ex vivo on 3 types of endothelial cells (TDECs, MBMECs and HUVECs). Axitinib administration disrupted the tube formations of MBMECs and HUVECs in a concentrationdependent manner; the half maximal inhibitory concentrations (IC50) were 13.68 μ M (MBMEC) and 5.45 μ M (HUVEC) (Figure 3A,B). In contrast, axitinib and LEAF had no impact on TDEC tube formation (Figure 3A,C,D). VEGFR-2 was not expressed in TDECs (Figure 1H). These results suggested that tube formation of TDECs occurred through an VEGF-independent angiogenesis pathway. On the other hand, undifferentiated 005 and U87 Δ EGFR did not show obvious tube formation in culture at 24h on Matrigel (Figure S3). Volcano plots from RNA-seq data of MBMECs and TDECs showed that Kdr (VEGFR-2) and Tek (Tie2) were significantly decreased in the TDECs compared with those in the MBMECs (Figure 3E). We analyzed the significantly upregulated genes in TDECs related to tumor growth factors and selected Angpt2, Lama4, Egr1, Egr3, and Vegfa. Principal component analysis and hierarchical clustering heatmap and enrichment analysis revealed that the TDEC group was enriched in blood vessel morphogenesis (51 genes, -LogP=9.416) compared with the MBMEC group (Figure 3F,G and Figure S2). Gene signature of TDEC group highly associated with vascular proliferation.

3.4 | Screening of New Anti-Angiogenic Agents Targeting TDEC Tumor Blood Vessels by Drug Repositioning

Based on the above results and previous reports, we used the TDEC tube formation assay as an ex vivo VEGF-independent tumor vascular screening model [23–25]. Total tube length was measured and its IC50 was evaluated to quantitatively compare screening drugs and to determine the drug concentration to be used in the mouse model. Furthermore, when targeting glioblastoma that highly infiltrates the normal brain, novel candidate drugs must pass through the BBB. We listed 19 antidepressants and anxiolytics with demonstrated ability to cross the BBB and with relatively low toxicity (Figure 4A and Figure S4). Tube formation of TDECs was detected at 6h and was almost completed in 24h (Figure 4B). The results showed that sertraline, a selective serotonin reuptake inhibitor (SSRI) antidepressant, had the strongest concentration-dependent inhibitory effect on tube formation of TDECs, while etizolam, a benzodiazepine anxiolytic, had no inhibitory effect (Figure 4C-E). We further found that sertraline had no inhibitory effect on tube formation of MBMECs (Figure 4C,F). The IC50 of sertraline for tube formation of TDECs was 4.64 µM, which was the lowest level of the 19 drugs (Figure 4D; Figures S5 and S6). We next examined the growth inhibitory activity of sertraline on two types of endothelial cells (TDECs and MBMECs) and neural cells and glial cells differentiated from 005 by WST-1 assays. Sertraline showed a growth inhibitory effect against TDECs at 10µM, whereas no growth inhibition was observed in the other two groups up to 10 µM (Figure 4G–I and Figure S7).




FIGURE 3 | Legend on next page.

FIGURE 3 | Response of TDECs and mouse brain microvascular endothelial cells (MBMECs) to anti-angiogenic drugs and genetic analysis. (A) Tube formation assay using vascular endothelial cells at 24 h and evaluation of anti-angiogenic effects under axitinib administration or VEGF-free conditions (bar: 500 µm). (B) Quantitative results of total tube length of tube formation of TDECs, MBMECs, and HUVECs treated with axitinib. (n=4). (C) Tube formation assay using TDECs with LEAF (bar: 500 µm). (D) Quantitative results of total tube length of TDECs treated with LEAF (n=4). (E) Volcano plot analysis of TDECs and MBMECs (q<0.05, \log_2 fold change (gene expression of MBMEC/TDEC) > 1 or <-1). F, Principal component analysis (PCA) and heatmap of all expressed genes of MBMECs versus TDECs detected by RNA-Seq (n=3). (G) Enrichment analysis of GO terms associated with up-regulated genes in TDECs compared with genes in MBMECs (q<0.05, \log_2 fold change (gene expression of TDEC/MBMEC) > 1).

These results suggest that sertraline, identified in an ex vivo drug screening, may be a potential and safe candidate as a novel anti-angiogenic drug targeting TDECs.

3.5 | Anti-Angiogenic Mechanism of Sertraline in Tumor Blood Vessels Composed of TDECs

We performed in vitro RNA-seq on TDECs before and after sertraline (5 μ M) administration (biological replicates, n=3) and hierarchical clustering heatmap (Figure 5A). We focused on the gene signature related to blood vessel endothelial cell migration in enrichment analysis (-LogP = 2.590) (Figure 5B and Figure S1). We also focused on angiogenesis-related genes that were significantly suppressed after sertraline administration from genes differentiated by the volcano plot (q = 0.05, $Log_2FC < -1$ or $1 < Log_2FC$) (Figure 5C,D) and selected 5 genes, Lama4, Egr3, Egr1, Fos, and Angpt2. Egr3, Egr1, and Fos are VEGF pathway-dependent vascular growth factors, and Lama4 and Angpt2 are VEGF-independent vascular growth factors. We examined the mRNA expression of the 5 genes in 005 cells and MBMECs (Figure 5E). Kdr (VEGFR-2) and Vegfa (VEGFA) genes, which play an important role in the VEGF pathway, were also evaluated, but these were not affected by sertraline administration. In addition, the expression of Tek (ANGPT1R, a receptor for Angiopoietin-2), was low in 3 groups except for MBMECs (Figure 5F). There were no expressions of the sertraline target receptor, SLC6A4 (Serotonin Transporter), in 005 cells and TDECs. In the secreted Angiopoietin-2 treated with sertraline, the increase of Angiopoietin-2 in controls on Days 3 and 5 and a suppression of Angiopoietin-2 secretion in the sertraline-administered group at both time points were observed (Figure 5G). These results showed that sertraline had a broad spectrum of anti-angiogenic effects, mainly on the non-VEGF pathway.

3.6 | Combination of Axitinib and Sertraline Prolonged Survival in a GSC Mouse Brain Tumor Model Resistant to VEGF Pathway Inhibitors

At 2 weeks after intracerebral transplantation of 005 cells, mice were treated with sertraline alone or combined with axitinib (Figure 6A-D). The axitinib monotherapy had no therapeutic

effect in 005 mouse model (Figures 2H and 6C,D). MRI and IHC of the tumors at 4 weeks after transplantation and 2 weeks after treatment showed a trend toward tumor reduction in the axitinib + sertraline combination group compared with the control, axitinib, and sertraline groups (Figure 6B). Kaplan-Meier survival curve analysis showed improved survival days in the axitinib + sertraline combination group (log-rank test p = 0.0403) (Figure 6C). There were no differences between the median survival days of the control, axitinib and sertraline groups $(35.7 \pm 1.42 \text{ (SE)}, 38.0 \pm 1.51 \text{ (SE)} \text{ and } 34.9 \pm 1.5 \text{ (SE)}$ days, respectively); however, the median survival days was 42.7 ± 1.69 (SE) days in the axitinib + sertraline combination group, indicating a prognostic benefit of approximately 20% (unpaired *t*-test, p = 0.0142) (Figure 6D). In brain tumor samples on Day 28, tumor blood vessels of both types (TDECs and non-TDECs) were significantly reduced in the axitinib + sertraline combination group compared with those in the control group (p=0.0286) (Figure 6E,F). These results in vivo suggest that sertraline alone has no effect on the differentiation or growth of GSCs. Furthermore, in the combination group, some necrosis from ischemia was observed as well as marked tumor vascular inhibition (Figure 6E,F).

These data indicated that one of the causes of resistance to anti-VEGF pathway inhibitors was increased angiogenesis by TDECs differentiated from GSCs. They also indicated that the combination of anti-VEGF pathway inhibitors and sertraline prolonged survival (Figure 7).

4 | Discussion

The key points of this study are "focusing on tumor blood vessels consisting of TDECs differentiated from GSCs as one of the causes of resistance to anti-VEGF pathway inhibitors" and "developing novel angiogenesis inhibitors for TDECs by repositioning existing drugs in the BBB passage". Anti-VEGF pathway inhibitors are an attractive therapy for various cancers but have limited therapeutic effects for glioblastoma, such as improvement of radiation necrosis and improvement of ADL because of reduced edema [26–28]. Fluvoxamine, an antidepressant identified by drug repositioning, shows efficacy against glioblastoma tumor invasion through the inhibition of invasive process formation [29]. Another study showed that

FIGURE 4 | Drug screening using tube formation assays. (A) The Schema of drug screening using the ex vivo TDEC tube formation assay. (B) Fluorescence imaging of tube formation on Matrigel using TDECs differentiated from 005 cells (bar: $500 \mu m$). (C) Tube formation assays in TDECs or MBMECs treated with the candidate drugs (bar: $500 \mu m$). (D–F) IC50 of the inhibitory effect of the candidate drugs for TDEC- or MBMEC-derived angiogenesis. (G–I) Cytotoxicity of sertraline for TDECs (G), MBMECs (H), or neural cells and glial cells from 005 (I) was measured using WST-1 assays. * indicates significant difference.




FIGURE 4 | Legend on perivous page.




FIGURE 5 | RNA-seq of TDECs treated with sertraline. (A) Hierarchical clustering heatmap using RNA-seq in control TDECs and TDECs treated with sertraline for 24h (each n = 3). (B) Enrichment analysis of GO terms associated with down-regulated genes in treated TDECs compared with genes in control TDECs (q < 0.05, \log_2 fold change (gene expression of treated/controls < -1). (C) Volcano plot analysis of data from RNA-seq (q < 0.05, \log_2 fold change (gene expression of treated/controls < -1). (C) Volcano plot analysis of data from RNA-seq (q < 0.05, \log_2 fold change (gene expression of treated/controls) > 1 or < -1). D, Angiogenesis gene set expressions in treated TDECs compared with those in control TDECs (\log_2 fold change (gene expression of treated/controls) > 1 or < -1). (E, F) Gene expression of genes associated with vascular proliferation in 005 cells, TDECs, TDECs treated with sertraline, and MBMECs (Lama4: p = 0.0001, Egr3: p = 0.0027, Egr1: p < 0.0001, Angpt2: p < 0.0001, and Tek, Kdr, and Vegfa: p > 0.05, TDECs treated with sertraline vs. TDECs). (G) ELISA of Angiopoieting-2 secreted into TDEC culture medium. * indicates significant difference.

the combination of the antidepressant imipramine and bevacizumab is effective in immunopotentiation [30]. Targeting glioblastoma, a highly invasive cancer, requires strategic therapy, such as combining BBB-passing agents with other anticancer agents [30]. In this study, we demonstrated the efficacy of a combination therapy strategy using antiangiogenic therapy using anti-VEGF pathway inhibitors. Targeting the tumor vasculature is a potent therapeutic strategy for glioblastoma as well as other malignancies.

The tumor vasculature in glioblastoma is composed of various types of endothelial cells (ECs), including normal brain ECs, bone marrow-derived ECs, mesenchymal stem cell-derived ECs, and TDECs [18]. In this study, we focused on the effects of tumor vessels composed of TDECs differentiated from GSCs and developed therapeutic agents targeting TDECs tumor vessels. Previous reports and our results suggested that some GSCs and TDECs do not express VEGFR-2 and exhibit angiogenic activity through a non-VEGF pathway [31]. Although TDECs were relatively rare in untreated tumors, we found that anti-VEGF pathway inhibition significantly increased TDECs in a reactive manner [32]. Thus, anti-angiogenic therapies that inhibit the VEGF pathway induced endothelial cell switching in tumor vessels, one of the causes of treatment resistance. Targeting TDECs complements the limitations of anti-VEGF antibody therapy, with reduced side effects on normal blood vessels. Various clinical trials have been conducted on treatments in primary and recurrent glioblastoma that target the tumor vasculature through non-VEGF pathway factors [33, 34]. These factors include the Angiopoietin-2 (PF-04856884), PDGFR (plateletderived growth factor receptor) and FLT3 (FMS-like tyrosine kinase 3) (MLN518), EGF, HER2 and Ephrin B4 (NCT02844439). However, the clinical trials have not yielded the expected results [35-38]. Novel anti-angiogenic inhibitors for non-VEGF pathways in other malignancies have been explored in glioblastoma, but the BBB is a problem for drug delivery [39]. The advantages of the drug positioning approach are that the candidate drugs are already available and have been demonstrated as safe, which significantly reduces drug development costs. Notably, we focused on drugs that reliably pass the BBB, which is the biggest obstacle to developing therapeutic agents for glioblastoma. Additionally, antidepressants are known to accumulate in high concentrations in the brain [40].

Some reports suggest that antidepressant use in glioblastoma does not prolong overall survival (OS) [41]. However, the Mayo Clinic reported a trend toward improved prognosis in patients

with glioblastoma in the group that used antidepressants in addition to standard therapy [42]. In addition, the anti-tumor effect of SSRI was observed at the animal experimental level [29]. Our results showed no expression of SLC6A4 (Serotonin Transporter), the target receptor for sertraline. Sertraline was thought to act through a pathway different from the serotonin pathway similar to other SSRIs. Our gene analysis results suggest that the anti-angiogenic mechanism of sertraline may occur through the inhibition of TDEC-derived angiogenesis via suppression of various pathways and genes including Angpt2, Lama4, Egr1, Egr3, and Fos genes. Angiopoietin-2 (Angpt2) acts as both an agonist and antagonist for the TIE2 receptor. The conditions depend on the concentration of angiopoietin-2 and the environment of the secretory cell, such as inflammation, tumor, and the presence of integrins [43, 44]. LAMA-4, Laminin Subunit Alpha 4, is specifically secreted by brain tumor cell lines and gliomas. One study showed that a higher patient grade is associated with a greater amount of LAMA-4 secreted into the cerebrospinal fluid [45].

LAMA-4 inhibits tumor cell migration and growth along blood vessels and is thus an important target for tumor cell invasion and angiogenesis [46]. In the present study, we found that LAMA-4 expression increased during the differentiation of GSCs into TDECs and that its expression was suppressed by sertraline. LAMA-4 is not expressed in normal vascular endothelial cells; both Angiopietin-2 and LAMA-4 are expressed in renal cell carcinoma and have been reported as prognostic factors [47, 48]. The combination of an Ang/Tie-2 inhibitor (trebananib) targeting Ang-1, Ang-2, and Tie-2 receptors with a VEGF inhibitor was expected to have an effective anti-tumor effect on glioblastoma but did not show a prognostic benefit in a clinical trial (NCT01609790) [49]. Upregulation of compensatory mechanisms by VEGF inhibitors is difficult to overcome with a single pathway inhibition combination. Multiple pathway inhibition, including Angiopoietin-2 and LAMA-4, could be meaningful due to changes in multiple genes, as in the present study with Sertraline, and further detailed exploration of pharmacological mechanisms is required.

In conclusion, our results suggested that TDECs may be one of the causes of resistance to anti-VEGF pathway inhibitors in the 005. These results suggested that sertraline was one of the novel therapeutic candidates against TDECs and could safely and effectively improve the prognosis of glioblastoma patients. Anti-angiogenic treatment combinations targeting various pathways showed the potential to be a new treatment option for glioblastoma.




FIGURE 6 | Legend on next page.

FIGURE 6 | Combination treatment of axitinib and sertraline in 005 mouse model. (A) Experimental overview. (B) T1-Gadolinium (Gd) image of MRI and HE-stained and nuclear-stained histology in tumor sections 2 weeks after treatment (scale bar: 1 mm). (C) Kaplan–Meier survival curves of the indicated groups (each n = 6 or 7) (log-rank test p = 0.0403). (D) Graph of median survival time of the indicated groups (each n = 6 or 7) (control vs. combination of axitinib and sertraline, unpaired *t*-test, p = 0.0142). (E) Comparison of tumor blood vessels in tumors by IHC of CD31 in the indicated groups. (F) Number of tumor blood vessels in tumors in the indicated groups and the ratio of TDEC/non-TDEC in IHC data (control vs. combination of axitinib and sertraline; p = 0.0286).




FIGURE 7 | Graphic abstract of combined sertraline and anti-VEGF therapy to glioblastoma. Right: Anti-angiogenic therapy with VEGF pathway inhibition induces TDEC differentiation from glioma stem like cells, resulting in no therapeutic effect. Left: Combination therapy with a VEGF pathway inhibitor and sertraline (SSRI), TDEC-targeted drug discovered through drug repositioning screening, provides new anti-tumor and prognostic effects.

Author Contributions

Nobushige Tsuboi: data curation (lead), formal analysis (lead), methodology (lead), project administration (equal), resources (lead), software (lead), validation (lead), visualization (lead), writing – original draft (equal). Yoshihiro Otani: methodology (equal), resources (supporting), supervision (equal). Atsuhito Uneda: formal analysis (supporting), methodology (supporting), software (supporting), supervision (equal). Joji Ishida: investigation (supporting), supervision (equal). Yasuki Suruga: project administration (equal). Yuji Matsumoto: supervision (equal). Atsushi Fujimura: methodology (supporting), supervision (equal). Kentaro Fujii: supervision (equal). Hideki Matsui: investigation (supporting), resources (supporting). Kazuhiko Kurozumi: investigation (supporting), supervision (equal). Isao Date: investigation (supporting), resources (equal), supervision (equal). Hiroyuki **Michiue:** conceptualization (lead), funding acquisition (lead), investigation (equal), project administration (lead), resources (equal), supervision (equal), visualization (equal), writing – original draft (equal), writing – review and editing (lead).

Acknowledgments

The mouse GSC (005) was kindly provided by Prof. I. Verma and Dr. T. Marumoto at the Laboratory of Genetics at the Salk Institute. Dr. Y. Soda at the Salk Institute provided technical information for culturing 005 cells. Prof. Y. Oike and Pro. K. Tomizawa at Kumamoto University provided research advice. We thank Dr. H. Nakayama and Dr. S. Tatekabe for their key experimental contributions related to this project and Ms. A. Ueda for her excellent technical assistance in our lab. We thank Gabrielle White Wolf, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

Ethics Statement

This study was approved by the research ethics committee of the Okayama University (approval nos. G1608-026 and 1911–023). All animal studies were performed following Okayama University ethical guidelines for experimental animal care (OKU-2018838, OKU-2019568, OKU-2020793, OKU-2021590).

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The article includes all data in the study, and further inquiries can be directed to the corresponding author.

References

1. H. A. Fine, "Bevacizumab in Glioblastoma — Still Much to Learn," *New England Journal of Medicine* 370 (2014): 764–765.

2. P. C. De Witt Hamer, S. G. Robles, A. H. Zwinderman, H. Duffau, and M. S. Berger, "Impact of Intraoperative Stimulation Brain Mapping on Glioma Surgery Outcome: A Meta-Analysis," *Journal of Clinical Oncology* 30 (2012): 2559–2565.

3. R. Stupp, W. P. Mason, M. J. van den Bent, et al., "Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma," *New England Journal of Medicine* 352 (2005): 987–996.

4. L. L. Muldoon, C. Soussain, K. Jahnke, et al., "Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check," *Journal of Clinical Oncology* 25 (2007): 2295–2305.

5. H. K. Brar, J. Jose, Z. Wu, and M. Sharma, "Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery," *Pharmaceutics* 15 (2022): 59.

6. S. Alomari, I. Zhang, A. Hernandez, et al., "Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature," *Biomolecules* 11 (2021): 1870.

7. Y. Itatani, K. Kawada, T. Yamamoto, and Y. Sakai, "Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway," *International Journal of Molecular Sciences* 19 (2018): 1232.

8. R. S. Kerbel, "Tumor Angiogenesis," New England Journal of Medicine 358 (2008): 2039–2049.

9. S. D. Markowitz and M. M. Bertagnolli, "Molecular Origins of Cancer: Molecular Basis of Colorectal Cancer," *New England Journal of Medicine* 361 (2009): 2449–2460.

10. R. A. Burger, M. F. Brady, M. A. Bookman, et al., "Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer," *New England Journal of Medicine* 365 (2011): 2473–2483.

11. S. Yano, Y. Matsumori, K. Ikuta, H. Ogino, T. Doljinsuren, and S. Sone, "Current Status and Perspective of Angiogenesis and Antivascular Therapeutic Strategy: Non-small Cell Lung Cancer," *International Journal of Clinical Oncology* 11 (2006): 73–81.

12. E. Van Cutsem, J. Tabernero, R. Lakomy, et al., "Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen," *Journal of Clinical Oncology* 30 (2012): 3499–3506.

13. C. Antoniotti, D. Rossini, F. Pietrantonio, et al., "Upfront FOLFOX-IRI Plus Bevacizumab With or Without Atezolizumab in the Treatment of Patients With Metastatic Colorectal Cancer (AtezoTRIBE): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial," *Lancet Oncology* 23 (2022): 876–887. 14. B. J. Kim, J. H. Jeong, J. H. Kim, H. S. Kim, and H. J. Jang, "The Role of Targeted Agents in the Adjuvant Treatment of Colon Cancer: A Meta-Analysis of Randomized Phase III Studies and Review," *Oncotarget* 8 (2017): 31112–31118.

15. W. Wick, T. Gorlia, M. Bendszus, et al., "Lomustine and Bevacizumab in Progressive Glioblastoma," *New England Journal of Medicine* 377 (2017): 1954–1963.

16. M. R. Gilbert, J. J. Dignam, T. S. Armstrong, et al., "A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma," *New England Journal of Medicine* 370 (2014): 699–708.

17. O. L. Chinot, W. Wick, W. Mason, et al., "Bevacizumab Plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma," *New England Journal of Medicine* 370 (2014): 709–722.

18. S. Rosinska and J. Gavard, "Tumor Vessels Fuel the Fire in Glioblastoma," *International Journal of Molecular Sciences* 22 (2021): 6514.

19. Y. Soda, T. Marumoto, D. Friedmann-Morvinski, et al., "Transdifferentiation of Glioblastoma Cells Into Vascular Endothelial Cells," *Proceedings of the National Academy of Sciences of the United States of America* 108 (2011): 4274–4280.

20. L. Ricci-Vitiani, R. Pallini, M. Biffoni, et al., "Tumour Vascularization via Endothelial Differentiation of Glioblastoma Stem-Like Cells," *Nature* 468 (2010): 824–828.

21. R. Wang, K. Chadalavada, J. Wilshire, et al., "Glioblastoma Stem-Like Cells Give Rise to Tumour Endothelium," *Nature* 468 (2010): 829–833.

22. T. Marumoto, A. Tashiro, D. Friedmann-Morvinski, et al., "Development of a Novel Mouse Glioma Model Using Lentiviral Vectors," *Nature Medicine* 15 (2009): 110–116.

23. Y. Zhao, J. Dong, Q. Huang, M. Lou, A. Wang, and Q. Lan, "Endothelial Cell Transdifferentiation of Human Glioma Stem Progenitor Cells In Vitro," *Brain Research Bulletin* 82 (2010): 308–312.

24. R. Auerbach, R. Lewis, B. Shinners, L. Kubai, and N. Akhtar, "Angiogenesis Assays: A Critical Overview," *Clinical Chemistry* 49 (2003): 32–40.

25. Y. Liu, X. Xu, Y. Zhang, et al., "Paradoxical Role of beta8 Integrin on Angiogenesis and Vasculogenic Mimicry in Glioblastoma," *Cell Death* & Disease 13 (2022): 536.

26. D. Lubelski, K. G. Abdullah, R. J. Weil, and N. F. Marko, "Bevacizumab for Radiation Necrosis Following Treatment of High Grade Glioma: A Systematic Review of the Literature," *Journal of Neuro-Oncology* 115 (2013): 317–322.

27. S. A. Climans, R. C. Ramos, P. A. Jablonska, D. B. Shultz, and W. P. Mason, "Bevacizumab for Cerebral Radionecrosis: A Single-Center Experience," *Canadian Journal of Neurological Sciences* 50, no. 4 (2022): 573–578, https://doi.org/10.1017/cjn.2022.64.

28. S. Hofer, K. Elandt, R. Greil, et al., "Clinical Outcome With Bevacizumab in Patients With Recurrent High-Grade Glioma Treated Outside Clinical Trials," *Acta Oncologica* 50 (2011): 630–635.

29. K. Hayashi, H. Michiue, H. Yamada, et al., "Fluvoxamine, an Anti-Depressant, Inhibits Human Glioblastoma Invasion by Disrupting Actin Polymerization," *Scientific Reports* 6 (2016): 23372.

30. A. Chryplewicz, J. Scotton, M. Tichet, et al., "Cancer Cell Autophagy, Reprogrammed Macrophages, and Remodeled Vasculature in Glioblastoma Triggers Tumor Immunity," *Cancer Cell* 40 (2022): 1111–1127.

31. M. G. Atzori, L. Tentori, F. Ruffini, et al., "The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Invasiveness of Human Glioblastoma and Glioblastoma Stem Cells," *Journal of Experimental & Clinical Cancer Research* 36 (2017): 106. 32. J. C. Carlson, M. Cantu Gutierrez, B. Lozzi, et al., "Identification of Diverse Tumor Endothelial Cell Populations in Malignant Glioma," *Neuro-Oncology* 23 (2021): 932–944.

33. J. D. Schulte, M. K. Aghi, and J. W. Taylor, "Anti-Angiogenic Therapies in the Management of Glioblastoma," *Chinese Clinical Oncology* 10 (2021): 37.

34. P. Aldaz and I. Arozarena, "Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?," *Cancers (Basel)* 13, no. 22 (2021): 5799.

35. T. T. Batchelor, E. R. Gerstner, X. Ye, et al., "Feasibility, Phase I, and Phase II Studies of Tandutinib, an Oral Platelet-Derived Growth Factor Receptor-Beta Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma," *Neuro-Oncology* 19 (2017): 567–575.

36. S. H. Kizilbash, S. K. Gupta, K. E. Parrish, et al., "In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May be Limited by Tissue Binding and Compensatory Signaling," *Molecular Cancer Therapeutics* 20 (2021): 1009–1018.

37. J. Kloepper, L. Riedemann, Z. Amoozgar, et al., "Ang-2/VEGF Bispecific Antibody Reprograms Macrophages and Resident Microglia to Anti-Tumor Phenotype and Prolongs Glioblastoma Survival," *Proceedings of the National Academy of Sciences of the United States of America* 113 (2016): 4476–4481.

38. Y. Odia, J. Sul, J. H. Shih, et al., "A Phase II Trial of Tandutinib (MLN 518) in Combination With Bevacizumab for Patients With Recurrent Glioblastoma," *CNS Oncology* 5 (2016): 59–67.

39. J. J. Vredenburgh, A. Desjardins, J. E. Herndon, 2nd, et al., "Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme," *Journal of Clinical Oncology* 25 (2007): 4722–4729.

40. E. Petrosyan, J. Fares, A. Cordero, et al., "Repurposing Autophagy Regulators in Brain Tumors," *International Journal of Cancer* 151 (2022): 167–180.

41. D. Gramatzki, J. L. Rogers, M. C. Neidert, et al., "Antidepressant Drug Use in Glioblastoma Patients: An Epidemiological View," *Neuro-Oncology Practice* 7 (2020): 514–521.

42. J. S. Caudill, P. D. Brown, J. H. Cerhan, and T. A. Rummans, "Selective Serotonin Reuptake Inhibitors, Glioblastoma Multiforme, and Impact on Toxicities and Overall Survival: The Mayo Clinic Experience," *American Journal of Clinical Oncology* 34 (2011): 385–387.

43. D. Gerald, S. Chintharlapalli, H. G. Augustin, and L. E. Benjamin, "Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy," *Cancer Research* 73 (2013): 1649–1657.

44. R. G. Akwii, M. S. Sajib, F. T. Zahra, and C. M. Mikelis, "Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology," *Cells* 8 (2019): 471.

45. T. Kohata, S. Ito, T. Masuda, T. Furuta, M. Nakada, and S. Ohtsuki, "Laminin Subunit Alpha-4 and Osteopontin Are Glioblastoma-Selective Secreted Proteins That Are Increased in the Cerebrospinal Fluid of Glioblastoma Patients," *Journal of Proteome Research* 19 (2020): 3542–3553.

46. S. Nagato, K. Nakagawa, H. Harada, et al., "Downregulation of Laminin alpha4 Chain Expression Inhibits Glioma Invasion In Vitro and In Vivo," *International Journal of Cancer* 117 (2005): 41–50.

47. B. A. Gayed, J. Gillen, A. Christie, et al., "Prospective Evaluation of Plasma Levels of ANGPT2, TuM2PK, and VEGF in Patients With Renal Cell Carcinoma," *BMC Urology* 15 (2015): 24.

48. J. W. Wragg, J. P. Finnity, J. A. Anderson, et al., "MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome," *Cancer Research* 76 (2016): 2314–2326.

49. D. A. Reardon, A. B. Lassman, D. Schiff, et al., "Phase 2 and Biomarker Study of Trebananib, an Angiopoietin-Blocking Peptibody, With and Without Bevacizumab for Patients With Recurrent Glioblastoma," *Cancer* 124 (2018): 1438–1448.

Supporting Information

Additional supporting information can be found online in the Supporting Information section.